Health Care · Pharmaceutical Preparations

WVE Wave Life Sciences Ltd. SEC Filings & Insider Trading Activity 2026

company
CIK 1631574115 filings
Russell 2000

WVE at a glance

Wave Life Sciences Ltd. (WVE, SEC CIK 1631574) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Wave Life Sciences Ltd. (WVE) reported revenue of $42.7 million (down 60.5% from FY2024) and a net loss of $204.4 million. Diluted EPS was -$1.21.
  • As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Wave Life Sciences Ltd. (WVE) shares worth $329.9 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$42.7M
−60.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
28 funds
$329.9M · +1 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 5.02 · Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Clinical-stage biotech developing RNA medicines using proprietary PRISM® platform combining multi-modal RNA-targeting modalities and chemistry innovations
  • New emphasis on obesity program WVE-007 showing positive Phase 1 data with durable fat loss and muscle preservation, supporting once or twice yearly dosing
  • Strategic focus shift to RNA editing (AIMers) for rare genetic diseases like AATD (WVE-006) and PNPLA3 liver disease (WVE-008), advancing first-in-class oligonucleotide therapies
  • Clinical pipeline update: WVE-N531 for Duchenne muscular dystrophy granted FDA Rare Pediatric Disease and Orphan Drug Designations; FORWARD-53 trial showed functional muscle improvements
  • Noteworthy: Accelerated regulatory engagement initiated for WVE-006 AATD program with potential accelerated approval pathway feedback expected mid-2026

Risk Factors

  • Cybersecurity risk oversight by Audit Committee with quarterly updates on incidents and mitigation activities
  • Executive team including Data Security Officer and CFO with 50+ years combined cybersecurity experience managing risk
  • Incident response plan and reporting thresholds ensure timely Board-level awareness of significant cybersecurity breaches

Management Discussion & Analysis

  • Revenue $42.7M in 2025 vs $108.3M in 2024, down $65.6M YoY due to Takeda agreement termination offset by GSK revenue increase
  • Operating loss widened to $215.4M in 2025 from $110.4M in 2024; operating margin -503.8% in 2025 vs -102.0% in 2024 (calculated as loss/ revenue)
  • Best segment R&D expenses: Other R&D including PNPLA3 and preclinical up $27.8M to $139.2M in 2025; worst segment HD program down $9.1M to $2.7M in 2025
  • Cash flow: Operating cash outflow $187.5M in 2025; financing inflows $488.2M driven by $377.8M public offering and $94.6M ATM sales; capex $0.7M in 2025
  • Outlook: Cash balance $602.1M at end 2025; expects funding sufficiency for 12+ months; notes risks in raising future capital tied to market conditions and business strategy

AI summary of the WVE 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $13.2M, up $5.6M YoY from $7.6M, entirely from the GSK Collaboration Agreement
  • Net loss $61.9M vs $53.9M YoY, operating loss $66.0M vs $56.4M
  • Highest program spending: other R&D $40.5M, up $5.7M; INHBE $6.4M, up $1.8M
  • Cash and equivalents $197.3M, marketable securities $233.4M; operating cash use $173.3M through nine months
  • Outlook: liquidity expected to fund operations at least twelve months; additional financing may be needed, with clinical data expected in fourth quarter 2026

Risk Factors

  • No material changes to risk factors identified in the 2026 Form 10-Q
  • Carried-forward risks remain those disclosed in Wave Life Sciences’ 2025 Form 10-K

AI summary of the WVE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stockholders approved 11,000,000 additional shares for the 2021 Equity Incentive Plan
  • Expanded equity pool supports employee retention and hiring, but increases potential shareholder dilution

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 84% quorum: 166.2M of 197.2M eligible shares represented at the November 12 annual meeting
  • Nine incumbent directors re-elected through the 2027 annual meeting, with Ken Takanashi receiving the highest withheld vote count at 22.7M
Filed Oct 27, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full earnings release furnished as Exhibit 99.1, providing the detailed financial and operating results investors need to assess performance

Item EX-99.1: Item EX-99.1

  • Cash, equivalents and securities $431.0M, plus $12M GSK milestone, funding operations into 3Q 2028
  • WVE-006 planning advances toward registrational trial, with one-year interim analysis targeting potential accelerated approval
Filed Jul 30, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full earnings details furnished in Exhibit 99.1 for investor review

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation furnished July 30, 2026, providing investors with current business and pipeline information
  • Exhibit 99.2 contains the presentation and should be reviewed for substantive operational or clinical updates

Item EX-99.1: Item EX-99.1

  • Q2 2026 results: revenue $2.3M, R&D $51.3M, net loss $69.4M versus $50.5M loss
  • Cash, equivalents, and marketable securities $490.6M, supporting operations into 3Q 2028

Item EX-99.2: Item EX-99.2

  • Corporate presentation highlights WVE-007 obesity and WVE-006 AATD programs, making clinical execution the key near-term valuation driver
  • WVE-007 Phase 2a INLIGHT trial underway in high-BMI participants, with combination and maintenance trials expected in 2H 2026

AI summaries of WVE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for WVE

Don't miss the next WVE filing

  • Alerts as it files. A push when WVE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut WVE, by share count.
  • Ask anything. An AI agent that reads every WVE filing and answers with sources.

WVE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
TAKANASHI KENAOct 5, 2026-
TAKANASHI KENAOct 5, 2026-
Tan Aik NaAOct 5, 2026-
Tan Aik NaAOct 5, 2026-
HENRY CHRISTIAN OAOct 5, 2026-
RA CAPITAL MANAGEMENT, L.P.AOct 5, 2026-
Verdine Gregory L.AOct 5, 2026-
RA CAPITAL MANAGEMENT, L.P.AOct 5, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$108.3M$42.7M
Operating Income--$110.4M-$215.4M
Net Income-$57.5M-$97.0M-$204.4M
Op. Margin--101.9%-504.1%
Net Margin--89.6%-478.3%
Balance Sheet
Total Assets$274.9M$352.2M$638.5M
Equity-$209.5M$518.4M
ROE--46.3%-39.4%
Per Share
EPS$-0.54$-0.70$-1.21
Cash Flow
Operating CF--$151.0M-$187.5M
CapEx$1.1M$938K$718K

Source: XBRL data in Wave Life Sciences Ltd. (WVE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate WVE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
WVE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202628$329.9M
Q1 202627$350.8M
Q4 202526$933.2M
Q3 202525$259.8M
Q2 202525$210.5M
Q1 202525$127.8M
Q4 202421$166.4M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

WVE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 18, 2026Analysis-
8-KOct 27, 2026Analysis-
10-QOct 27, 2026Analysis
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
10-QJul 30, 2026Analysis
8-KJul 30, 2026Analysis-
8-KJun 26, 2026Analysis-
8-KMay 18, 2026Analysis
10-QApr 28, 2026Analysis
8-KApr 28, 2026Analysis-
8-KApr 21, 2026Analysis-
8-KApr 15, 2026Analysis-
4Mar 30, 2026--
8-KMar 26, 2026--

Related Health Care companies

All Health Care →

WVE SEC filings: frequently asked questions

Which institutions hold WVE stock?

As of June 30, 2026, the largest Wave Life Sciences Ltd. (WVE) holders among the 13F filers tracked by SignalX were BlackRock ($111.6 million), FMR LLC (Fidelity) ($28.6 million), State Street Corp ($28.1 million), Two Sigma Investments ($21.5 million), Morgan Stanley ($14.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was WVE's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Wave Life Sciences Ltd. (WVE) reported revenue of $42.7 million (down 60.5% from FY2024) and a net loss of $204.4 million. Diluted EPS was -$1.21. The figures come from the XBRL data in the 10-K.

What are the main risks in WVE's latest 10-K?

In the 10-K filed February 26, 2026, Wave Life Sciences Ltd. (WVE) flagged: Cybersecurity risk oversight by Audit Committee with quarterly updates on incidents and mitigation activities. Executive team including Data Security Officer and CFO with 50+ years combined cybersecurity experience managing risk. (AI summary of the Risk Factors section.)

What did WVE report in its latest 8-K?

Wave Life Sciences Ltd. (WVE) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved 11,000,000 additional shares for the 2021 Equity Incentive Plan.

What are the latest WVE SEC filings?

Wave Life Sciences Ltd. (WVE) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on October 7, 2026.

What is WVE's SEC CIK number?

Wave Life Sciences Ltd. (WVE)'s SEC Central Index Key (CIK) is 1631574. EDGAR lists every WVE filing under that number.

Ask anything about WVE

The research agent reads WVE's filings, financials, insider trades and 13F holders, then answers with sources.